B+
Bull case
30%
Probability
Target price
$28.00
+26.9% vs current
CDNA
CareDxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$25.20
+14.2% vs current
B-
Bear case
25%
Probability
Target price
$18.50
-16.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+59.4
Score
AI commentary
Headline buzz is high because earnings, the Eurobio divestiture, and the Naveris acquisition all hit within two weeks and the main earnings release came on April 28, 2026. Immediate market reaction was muted to slightly negative despite the beat and guidance raise, while T+1 analyst reaction was limited but included a BTIG target increase. With low formal coverage, no usable social packet, and a loose peer set, this is better framed as a cautious post-earnings monitoring setup than a high-conviction re-rating call.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-29catalystQ1 earnings reset improved the near-term setupHigh impact
CareDx reported Q1 revenue of $118 million, testing services revenue of $91 million, adjusted EBITDA of $19 million, and positive operating cash flow; its 10-Q also showed $77.9 million of cash plus $120.2 million of marketable securities at March 31, 2026 [#10-Q-2026-04-28]. The earnings release raised FY2026 revenue guidance to $447 million-$465 million from $420 million-$444 million and set adjusted EBITDA guidance at $43 million-$57 million.
2026-09-30catalystPortfolio reshaping could improve mix and margin profile through 2026High impact
CareDx agreed to divest its Lab Products business to Eurobio Scientific for $170 million in cash and said the move should simplify the operating model, improve financial flexibility, and support adjusted EBITDA margin expansion. Preliminary Q1 trends showed 48% growth in testing services and 33% growth in patient and digital solutions, supporting the higher-margin core-business focus.
2026-10-28eventNaveris acquisition closing is the main expansion eventHigh impact
The April 28, 2026 merger agreement for Naveris calls for $160 million in upfront cash plus up to $100 million of revenue-based milestone payments, with HSR and other customary closing conditions and an outside date of October 28, 2026 [#8-K-2026-04-28]. If completed, it would extend CareDx from transplant diagnostics into HPV-driven MRD testing.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology